Literature DB >> 10441041

Reducing the burden of diabetes: managing cardiovascular disease.

H Keen1, C Clark, M Laakso.   

Abstract

Of the threats to health and life that beset the person with diabetes, cardiovascular disease (CVD), particularly coronary heart disease (CHD) but also cerebrovascular and peripheral vascular disease, represent the heaviest burden. The relative risk for CVD is very high for Type 1 diabetes, but the absolute risk, in terms of numbers, is much higher for Type 2. In all societies, diabetes increases cardiovascular risk twofold or more, compared with the local non-diabetic population. Some of the evidence for this diabetes-related increase in cardiovascular risk is reviewed and its relationship to recognised cardiovascular risk factors considered. The explanation of the enhanced susceptibility to atherosclerotic disease in diabetes remains a matter of contention. How much can be explained by greater prevalence in diabetes of such risk factors as hypertension and dyslipidaemia? To what extent is the impact of a given level of risk factor magnified by a co-existing diabetic state? Is the increased cardiovascular morbidity and mortality secondary to risk factors specifically related to the diabetic state itself? Does the explanation lie in altered coagulability due to changes in platelet activation and aggregability, fibrinogen levels, Factor VII, von Willebrand factor or PAI-1, in the concentration or composition of plasma lipoproteins, in defective endothelial cell function or other metabolic abnormalities of the arterial wall? To what extent is cardiovascular risk related to the degree of hyperglycaemia, protein glycation, relative hyperinsulinaemia and insulin resistance? Data from recent epidemiological, intervention and laboratory investigations bearing on causation, management and prevention of CVD in diabetes are reviewed. Evidence for the impact of correction of glycaemia, dyslipidaemia and raised arterial pressure is considered and reasons are adduced for a broad and proactive therapeutic approach with early identification and vigorous correction of key risk factors. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10441041     DOI: 10.1002/(sici)1520-7560(199905/06)15:3<186::aid-dmrr30>3.0.co;2-5

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  8 in total

Review 1.  Peripheral arterial disease in diabetes: is there a role for genetics?

Authors:  Arabindra B Katwal; Ayotunde O Dokun
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

2.  SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes.

Authors:  Yi-Der Jiang; Yi-Cheng Chang; Yen-Feng Chiu; Tien-Jyun Chang; Hung-Yuan Li; Wen-Hsing Lin; Hsiang-Yu Yuan; Yuan-Tsong Chen; Lee-Ming Chuang
Journal:  BMC Med Genet       Date:  2010-08-25       Impact factor: 2.103

3.  Efficacy and Safety of Quinapril 40mg Once Daily as Monotherapy for Patients with Poorly Controlled Hypertension : The EUREKA Study.

Authors:  C Pueyo; C Diaz; J M Sol; X Masramon; G Hernández
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

4.  Histopathological abnormalities of prolonged alloxan-induced diabetes mellitus in rabbits.

Authors:  Sajad Hussain Mir; Mohd Maqbool Darzi
Journal:  Int J Exp Pathol       Date:  2009-02       Impact factor: 1.925

5.  An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia.

Authors:  S M Poucher; S Freeman; S J G Loxham; G Convey; J B Bartlett; J De Schoolmeester; J Teague; M Walker; A V Turnbull; A D Charles; F Carey; S Berg
Journal:  Br J Pharmacol       Date:  2007-10-15       Impact factor: 8.739

6.  Fermented milk, Kefram-Kefir enhances glucose uptake into insulin-responsive muscle cells.

Authors:  Kiichiro Teruya; Maiko Yamashita; Rumi Tominaga; Tsutomu Nagira; Sun-Yup Shim; Yoshinori Katakura; Sennosuke Tokumaru; Koichiro Tokumaru; David Barnes; Sanetaka Shirahata
Journal:  Cytotechnology       Date:  2002-11       Impact factor: 2.058

7.  The impact of demographic and risk factor changes on coronary heart disease deaths in Beijing, 1999-2010.

Authors:  Jun Cheng; Dong Zhao; Zhechun Zeng; Julia Alison Critchley; Jing Liu; Wei Wang; Jiayi Sun; Simon Capewell
Journal:  BMC Public Health       Date:  2009-01-22       Impact factor: 3.295

8.  Application of the modified Framingham cardiovascular risk score to newly diagnosed type 2 black African diabetic patients.

Authors:  Andre Pascal Kengne; Mesmin Dehayem; Simeon Pierre Choukem; Paschal Awah; Jean-Claude Mbanya
Journal:  Cardiovasc J Afr       Date:  2007 Jul-Aug       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.